View Older Stories View More Recent Stories

May 9, 2024 09:45AM Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024
May 9, 2024 08:33AM Neurocrine Biosciences (NBIX) Announces Initiation of Phase 1 Study of Effects of NBI-1076986
May 9, 2024 08:30AM Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults
May 8, 2024 08:30AM Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
May 7, 2024 04:15PM Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference
May 7, 2024 08:30AM Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficie
May 6, 2024 08:30AM Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring
May 3, 2024 01:15PM Neurocrine Biosciences (NBIX) Presented CAHtalyst Pediatric Study Baseline Characteristics and CAHtalog Registry Data
May 3, 2024 01:15PM Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024
May 1, 2024 07:00AM Neurocrine Biosciences Reports First Quarter 2024 Financial Results
Apr 30, 2024 05:12PM Neurocrine Biosciences (NBIX) Announces FDA Approval of INGREZZA SPRINKLE Capsules
Apr 30, 2024 05:12PM Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules
Apr 24, 2024 08:30AM Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community
Apr 23, 2024 07:01AM Neurocrine Biosciences (NBIX) Reports Positive Phase 2 Data for NBI-1065845
Apr 23, 2024 07:00AM Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
Apr 10, 2024 04:01PM Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results
Apr 3, 2024 08:31AM Neurocrine Biosciences (NBIX) Announces First-Patient Dosed in Phase 2 Clinical Study of NBI-1070770
Apr 3, 2024 08:30AM Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
Mar 28, 2024 08:31AM Neurocrine Biosciences (NBIX) Initiates Phase 1 Study of NBI-1065890
Mar 28, 2024 08:30AM Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
Mar 11, 2024 04:01PM Neurocrine Biosciences to Participate at Virtual Investor Conferences in March
Feb 27, 2024 04:01PM Neurocrine Biosciences to Participate at Investor Conferences in March
Feb 7, 2024 07:00AM Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024
Jan 17, 2024 04:16PM Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2023 Financial Results
Jan 2, 2024 04:01PM Neurocrine Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Dec 5, 2023 04:02PM Neurocrine Biosciences (NBIX) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Crinecerfont in Congenital Adrenal Hyperplasia
Dec 5, 2023 04:01PM Neurocrine Biosciences Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Crinecerfont in Congenital Adrenal Hyperplasia
Dec 1, 2023 07:00AM Neurocrine Biosciences to Host Analyst Day on December 5, 2023
Nov 13, 2023 07:01AM Neurocrine Biosciences (NBIX) Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation
Nov 13, 2023 07:00AM Neurocrine Biosciences Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation
Nov 9, 2023 04:01PM Neurocrine Biosciences Provides Development Pipeline Update
Nov 8, 2023 04:05PM Neurocrine Biosciences Launches Interactive Digital Tool for use by Healthcare Providers to Help Expand Education on Identifying and Diagnosing Tardive Dyskinesia
Nov 8, 2023 04:01PM Neurocrine Biosciences to Present at the Jefferies London Healthcare Conference
Nov 2, 2023 08:30AM Neurocrine Biosciences® Presents INGREZZA® (valbenazine) Capsules Interim Data Demonstrating Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 50 at Huntington Study
Oct 31, 2023 07:00AM Neurocrine Biosciences Reports Third Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance
Oct 10, 2023 04:01PM Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2023 Financial Results
Oct 5, 2023 07:02AM Neurocrine Bio (NBIX) Announces Phase 3 Pediatric Study Results of Crinecerfont in Children and Adolescents for Congenital Adrenal Hyperplasia Met Primary, Key Secondary Endpoints
Oct 5, 2023 07:00AM Neurocrine Biosciences Announces Phase 3 Pediatric Study Results of Crinecerfont in Children and Adolescents for the Treatment of Congenital Adrenal Hyperplasia Met Primary and Key Secondary Endpoints
Sep 21, 2023 09:15AM Neurocrine Biosciences Presents Post Hoc Data Analysis in Congenital Adrenal Hyperplasia at ESPE 2023
Sep 14, 2023 08:31AM Neurocrine Biosciences (NBIX) Announces U.S. FDA Accepts New Drug Application for INGREZZA® (valbenazine) Oral Granules Sprinkle Formulation
Sep 14, 2023 08:30AM Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Application for INGREZZA® (valbenazine) Oral Granules Sprinkle Formulation
Sep 12, 2023 07:30AM Neurocrine Biosciences (NBIX) Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont
Sep 12, 2023 07:30AM Neurocrine Biosciences Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH)
Sep 11, 2023 08:30AM Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
Aug 31, 2023 04:01PM Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
Aug 29, 2023 08:31AM Neurocrine Biosciences (NBIX) Presents Data at MDS International Congress of Parkinson's Disease and Movement Disorders
Aug 29, 2023 08:30AM Neurocrine Biosciences Presents Data at MDS International Congress of Parkinson's Disease and Movement Disorders® Demonstrating Comparable Improvement Over Time in Tardive Dyskinesia Severity and Imp
Aug 28, 2023 08:30AM Neurocrine Biosciences (NBIX) Presents New INGREZZA Capsules Data Demonstrating Early and Sustained Improvements
Aug 28, 2023 08:30AM Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Capsules Data Demonstrating Early and Sustained Improvements in Chorea Associated With Huntington's Disease
Aug 21, 2023 06:18AM Neurocrine Biosciences (NBIX) announces FDA approval of INGREZZA for Huntington's disease
View More Recent Stories View Older Stories